Ocugen, Inc. (NASDAQ:OCGN – Get Rating) CEO Shankar Musunuri sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $1.28, for a total transaction of $128,000.00. Following the transaction, the chief executive officer now directly owns 2,227,950 shares of the company’s stock, valued at $2,851,776. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Ocugen Stock Performance
OCGN opened at $1.21 on Friday. Ocugen, Inc. has a 12-month low of $1.09 and a 12-month high of $4.53. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $264.85 million, a PE ratio of -3.46 and a beta of 3.97. The firm has a 50 day moving average of $1.39 and a two-hundred day moving average of $1.94.
Ocugen (NASDAQ:OCGN – Get Rating) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). On average, analysts anticipate that Ocugen, Inc. will post -0.39 EPS for the current year.
Hedge Funds Weigh In On Ocugen
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
- Get a free copy of the StockNews.com research report on Ocugen (OCGN)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.